N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing and novel high value drugs with an unmet commercial or medical need.
N4’s commercial strategy is to advance a pipeline of products through clinical proof of concept and then partner to take the products through the relevant regulatory pathway studies to regulatory approval.
N4 has two proprietary platform delivery system technologies allowing it to improve cellular uptake of sub unit vaccines, cancer vaccines and therapeutics.
N4 has also acquired the rights to a range of patents from OPAL IP to allow it to reformulate a wide range of drugs using a range of techniques as well as its cocrystal approach.
Its first product in development is a 'reformulated' version of Sildenafil (Viagra) aimed at improving the onset of action and maintaining an effective dose of the drug during the therapeutic window to make it last longer.
In addition N4 is undertaking development work on its vaccine technology to produce a data pack to present to potential customers on how it can improve vaccine performance and is scaling up production to a robust process to allow commerical research on cancer and sub unit vaccines.